These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11357554)

  • 21. Everolimus: an immunosuppressive agent in transplantation.
    Patel JK; Kobashigawa JA
    Expert Opin Pharmacother; 2006 Jul; 7(10):1347-55. PubMed ID: 16805720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Conversion from a calcineurin inhibitor to a sirolimus-based therapy after renal transplantation - An update of existing recommendations].
    Arns W; Budde K; Eitner F; Gwinner W; Hugo C; Pressmar K; Weimann A; Witzke O
    Dtsch Med Wochenschr; 2011 Dec; 136(49):2554-9. PubMed ID: 22131077
    [No Abstract]   [Full Text] [Related]  

  • 23. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB; Grimm EM
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The development of sirolimus: The University of Texas-Houston experience.
    Kahan BD; Stepkowski SM; Napoli KL; Katz SM; Knight RJ; Van Buren C
    Clin Transpl; 2000; ():145-58. PubMed ID: 11512308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefit-risk assessment of sirolimus in renal transplantation.
    Kuypers DR
    Drug Saf; 2005; 28(2):153-81. PubMed ID: 15691225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients.
    El-Sabrout R; Weiss R; Butt F; Delaney V; Qadir M; Hanson P; Butt K
    Transplant Proc; 2002 Aug; 34(5):1942-3. PubMed ID: 12176636
    [No Abstract]   [Full Text] [Related]  

  • 28. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation.
    Vilalta R; Vila A; Nieto J; Callís L
    Transplant Proc; 2003 Mar; 35(2):703-4. PubMed ID: 12644102
    [No Abstract]   [Full Text] [Related]  

  • 29. Sirolimus (Rapamune) in renal transplantation.
    Johnson RW
    Curr Opin Nephrol Hypertens; 2002 Nov; 11(6):603-7. PubMed ID: 12394605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective analysis of a sirolimus/prograf regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts.
    Youseff N; Small S
    Transplant Proc; 2002 Aug; 34(5):1653-5. PubMed ID: 12176522
    [No Abstract]   [Full Text] [Related]  

  • 31. Tailoring immunosuppressive therapy for renal transplant recipients.
    Vanrenterghem YF
    Pediatr Transplant; 2001 Dec; 5(6):467-72. PubMed ID: 11737774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus, a potent new immunosuppressive drug for organ transplantation.
    Stepkowski SM
    Ann Transplant; 1996; 1(3):19-25. PubMed ID: 9869915
    [No Abstract]   [Full Text] [Related]  

  • 33. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW; Kreis H; Oberbauer R; Brattström C; Claesson K; Eris J
    Transplantation; 2001 Sep; 72(5):777-86. PubMed ID: 11571437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sirolimus: new preparation. No tangible advance in renal transplantation.
    Prescrire Int; 2002 Dec; 11(62):165-6. PubMed ID: 12469693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steroid immunosuppression in kidney transplantation: a passing era.
    Schulak JA
    J Surg Res; 2004 Mar; 117(1):154-62. PubMed ID: 15013726
    [No Abstract]   [Full Text] [Related]  

  • 37. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
    Pescovitz MD; Govani M
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five-year experience using sirolimus-based, calcineurin inhibitor-free immunosuppression in pediatric renal transplantation.
    Hymes LC; Warshaw BL
    Pediatr Transplant; 2011 Jun; 15(4):437-41. PubMed ID: 21338459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus: preventing organ rejection in adult kidney transplant recipients.
    Dantal J
    Expert Opin Pharmacother; 2012 Apr; 13(5):767-78. PubMed ID: 22404500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.